Bladder Cancer
Conditions
Keywords
bladder cancer, neoadjuvant chemotherapy, immunohistochemical biomarkers
Brief summary
Clinical trial to investigate the relationship between the expression of immunohistochemical biomarkers GATA-3, CK20, P53 and Ki67 in bladder cancer and pathological complete response after neoadjuvant chemotherapy.
Detailed description
This is a retrospective study included bladder cancer patients treated with neoadjuvant chemotherapy. We analyzed the changes in the expression of GATA-3, CK20, P53 and Ki67 before and after NAC. Evaluating the sensitivity factor for predicting pathological complete response.
Interventions
OTHERneoadjuvant chemotherapy
The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
Sponsors
First Affiliated Hospital, Sun Yat-Sen University
Third Affiliated Hospital, Sun Yat-Sen University
Shantou Central Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Any male or female patient aged 18 or older. 2. Histologically confirmed bladder cancer, cystectomy was performed after NAC. 3. Complete clinical data.
Exclusion criteria
1. Patients with severe organic disease who can not tolerate chemotherapy or surgery 2. Patients received previous treatment (chemotherapy, radiation, or molecular targeted therapy). 3. Patients with distant metastasis or other cancer history.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of immunohistochemical biomarkers GATA-3, CK20, P53 and Ki67 | 1 year |
| Tumor regression grade | 1 year |
Contacts
Primary ContactHao Chen
Outcome results
None listed